INmune Bio Inc (INMB)
9.46
-0.08
(-0.79%)
USD |
NASDAQ |
May 31, 16:00
9.475
+0.02
(+0.16%)
After-Hours: 20:00
INmune Bio Cash from Financing (Quarterly): -2.50M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -2.50M |
| December 31, 2023 | -2.50M |
| September 30, 2023 | -1.725M |
| June 30, 2023 | 0.00 |
| March 31, 2023 | 0.00 |
| December 31, 2022 | 0.00 |
| September 30, 2022 | 0.00 |
| June 30, 2022 | 0.00 |
| March 31, 2022 | 0.729M |
| December 31, 2021 | 0.00 |
| September 30, 2021 | 52.94M |
| June 30, 2021 | 14.95M |
| March 31, 2021 | 28.46M |
| Date | Value |
|---|---|
| December 31, 2020 | 0.00 |
| September 30, 2020 | 23.24M |
| June 30, 2020 | 0.664M |
| March 31, 2020 | -0.009M |
| December 31, 2019 | 0.00 |
| September 30, 2019 | 0.00 |
| June 30, 2019 | 4.958M |
| March 31, 2019 | 7.251M |
| December 31, 2018 | 0.00 |
| September 30, 2018 | 0.00 |
| June 30, 2018 | 0.00 |
| March 31, 2018 | 0.90M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-2.50M
Minimum
Dec 2023
52.94M
Maximum
Sep 2021
5.961M
Average
--
Median
Sep 2019
Cash from Financing (Quarterly) Benchmarks
| AVITA Medical Inc | 0.631M |
| Dare Bioscience Inc | 0.014M |
| Zevra Therapeutics Inc | 1.217M |
| Xeris Biopharma Holdings Inc | 35.19M |
| Kodiak Sciences Inc | 0.038M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -7.476M |
| Free Cash Flow | -18.32M |
| Free Cash Flow Per Share (Quarterly) | -0.4147 |
| Free Cash Flow to Equity (Quarterly) | -5.01M |
| Free Cash Flow Yield | -10.76% |